from24/7 Wall St.3 days agoBusinessMerck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term HeadwindsMerck's earnings beat expectations, but shares fell due to acquisition charges, with a price target of $135.70 indicating potential upside.
from24/7 Wall St.3 months agoHealthcareMerck Reports Earnings Tuesday Morning After Gaining 13% Over the Past YearMerck reports Q4 2025 earnings Feb. 3 before market; Street expects $2.01 EPS on $16.12B revenue; Keytruda, Gardasil, guidance and Verona integration are focus.
Businessfrom24/7 Wall St.3 days agoMerck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term HeadwindsMerck's earnings beat expectations, but shares fell due to acquisition charges, with a price target of $135.70 indicating potential upside.
from24/7 Wall St.3 months agoHealthcareMerck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year
Medicinefromwww.bbc.com5 days agoNHS cancer jab could mean patients spend hours less in hospitalA new injectable form of Keytruda will significantly reduce hospital time for cancer patients in the UK.
Cancerfromwww.dw.com3 weeks agoMerck's Keytruda: A lifesaving drug, a global divideKeytruda's success highlights disparities in global access to cancer treatment due to pricing, patents, and regulatory systems.
Medicinefromwww.bbc.com5 days agoNHS cancer jab could mean patients spend hours less in hospitalA new injectable form of Keytruda will significantly reduce hospital time for cancer patients in the UK.
Cancerfromwww.dw.com3 weeks agoMerck's Keytruda: A lifesaving drug, a global divideKeytruda's success highlights disparities in global access to cancer treatment due to pricing, patents, and regulatory systems.
